Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) announced that its gene synthesis and cell-free protein expression workflow was used in a recent study by Tencent AI for Life Sciences Lab, published in Nature Communications. The study demonstrated the rapid experimental validation of AI-designed proteins with improved activity, stability, and multifunctionality, addressing a key bottleneck in protein engineering.
Artificial intelligence has significantly accelerated protein amino acid sequence design, but translating computational designs into functional proteins remains challenging. Protein activity, stability, folding, and expression are influenced by complex structural and biochemical factors, often leading to discrepancies between in silico predictions and experimental outcomes. To bridge this gap, the study introduced an Ontology Reinforcement Iteration (ORI) framework, integrating protein ontology with reinforcement learning from wet-lab feedback. Experimental data, including protein expression levels and functional activity, were continuously fed back into the model, enabling iterative optimization of protein sequences and improved design accuracy.
The researchers utilized Sino Biological’s XPressMAX™ Cell-Free Protein Synthesis Kit to enable rapid protein expression and functional screening. Protein-coding sequences cloned into the kit’s expression vector and added to the proprietary cell-free reaction system supported rapid design–build–test cycles. Using this workflow, the team engineered a lysozyme with over 100-fold higher activity than the natural enzyme, developed a thermostable chitinase retaining activity at 85°C, and successfully expressed bifunctional enzymes with improved performance compared with naturally occurring multifunctional enzymes.
Key features of the XPressMAX™ Cell-Free Protein Synthesis Kit include ultra-fast synthesis with protein expression completed in as little as 3 hours, high screening efficiency optimized for VHH, scFv, and miniproteins, flexible template support compatible with plasmid and linear DNA templates, disulfide bond-friendly expression without additional enhancers, cost-effective performance, and scalable supply suitable for high-throughput and industrial applications.
The ability to rapidly validate AI-designed proteins has significant implications for the biotechnology industry, potentially accelerating the development of novel enzymes for industrial processes, therapeutics, and other applications. By enabling iterative optimization driven by experimental feedback, the ORI framework combined with cell-free protein synthesis could reduce the time and cost associated with protein engineering.
Sino Biological is an international reagent supplier and CRO service provider specializing in recombinant protein production and antibody development. With the US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech in Canada, the company delivers tailored solutions to researchers in over 90 countries. The original press release is available at www.newmediawire.com.
